Gelmetix is a technology company.
Gelmetix’s DXM is a biological solution that intervenes at the early phase of degenerative disc disease, providing a minimally invasive alternative to surgery.
Gelmetix has raised $9.0M across 2 funding rounds.
Gelmetix has raised $9.0M in total across 2 funding rounds.
Gelmetix has raised $9.0M in total across 2 funding rounds.
Gelmetix's investors include Omron Ventures.
Gelmetix is a UK-based medical device company developing injectable polymer gel technologies as non-invasive alternatives to surgery for chronic pain conditions like lower back pain and osteoarthritis.[1][2][3][4] Their lead product, DXM (double crosslinked microgel), targets degenerative disc disease by restoring disc water content, stabilizing structure, and relieving pain through a minimally invasive injection procedure, serving patients who seek drug-free options amid the opioid crisis.[3][4][5] With $12.8M in total funding across three rounds, including a recent $7M raise, the company shows strong growth momentum as DXM advances to clinical trials and a second product, SXM, progresses in preclinical development.[2][4]
Gelmetix was founded in 2012 as a spin-out from the University of Manchester, building on over 25 years of research by professors Tony Freemont (Osteoarticular Pathology) and Brian Saunders (Polymer and Colloid Chemistry).[1][4] The idea emerged from their deep insights into degenerative discs and joints, leading to a patented polymer gel that links microgel particles into injectable, load-bearing materials mimicking natural joint lubricants.[3][4][6] Early pivotal moments include scaling from lab production to ISO medical device approval, positioning for CE marking and clinical trials, with leadership from experts in medicine, business, and product launches driving initial traction.[4][5]
Gelmetix rides the wave of regenerative biomaterials and minimally invasive orthopedics, addressing a massive unmet need in chronic pain management—where back pain alone affects millions and drives opioid dependency.[3][4][5] Timing aligns with rising demand for non-pharmacological solutions post-opioid epidemic, aging populations, and advances in hydrogel tech for tissue repair.[4] Market forces like cost pressures on healthcare (offering affordable surgery alternatives) and regulatory pushes for innovative devices favor them, while their university spin-out roots amplify influence in the medtech ecosystem by bridging academic research to commercial therapies.[1][2][4]
Gelmetix is poised for breakthroughs with DXM's clinical trials potentially yielding CE approval, unlocking European markets and further funding for SXM and platform expansions like stem cell carriers.[2][4][5] Trends in personalized regenerative medicine, AI-optimized biomaterials, and global pain management shifts will shape their path, evolving them from a back-pain specialist to a broader therapeutic biomaterials leader.[3][4] As they scale, expect partnerships with orthopedics giants and influence in reducing surgical backlogs, transforming lives through restored mobility.[1][5]
Gelmetix has raised $9.0M across 2 funding rounds. Most recently, it raised $7.0M Series C in May 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2021 | $7.0M Series C | Omron Ventures | |
| Aug 1, 2018 | $2.0M Series B | Omron Ventures |